Expert Directory
Health Care, Health Care Policy, health care economics, Public Health, Johns Hopkins Bloomberg School Of Public Health, Johns Hopkins Carey Business School
Dan Polsky is a Bloomberg Distinguished Professor of Health Policy and Economics at Johns Hopkins University. Prior to joining Hopkins served as Executive Director of the Leonard Davis Institute of Health Economics from 2012 - 2019 and was a professor at the University of Pennsylvania in the Perelman School of Medicine and the Wharton School of Business. His research seeks an advanced understanding of the cost and quality tradeoff of health care intervention that addresses care, access, coverage, and payment.
causal inference, Economics, Behavioral Economics, Behavioral Science, Environmental Policy, Johns Hopkins, Johns Hopkins Carey Business School
Paul J. Ferraro, PhD, is the Bloomberg Distinguished Professor of Business and Engineering at Johns Hopkins University. Dr. Ferraro has a joint faculty appointment in the Whiting School of Engineering and the Carey Business School. His research focuses on behavioral economics and the design and evaluation of environmental programs in the private and public sectors. Because these research areas are multi-disciplinary and applied, he collaborates with scientists and engineers from a variety of social, natural and physical science disciplines, as well as practitioners in the field.
Phillip Phan, PhD
Alonzo and Virginia Decker Professor of Strategy and Entrepreneurship
Johns Hopkins University Carey Business SchoolTechnology Transfer and Commercialization, Entreprenership, Medicine, strategic management , Technology, Johns Hopkins, Johns Hopkins Carey Business School
Phillip Phan, PhD, is the Alonzo and Virginia Decker Professor of Strategy and Entrepreneurship and joined the Johns Hopkins Carey Business School in 2008. He is a professor in the research track with expertise in the areas of technology entrepreneurship and strategic management.
Marketing, Consumer decision-making, Decision Making, Inequality, Inefficiency, marketing cues, comparison shopping, consumer judgment, Preferences, Johns Hopkins Carey Business School
Meng Zhu is a professor at the Johns Hopkins Carey Business School and specializing in marketing and consumer decision-making. She joined the Carey Business School after receiving her PhD from Carnegie Mellon University. Her research interests include consumer judgment and decision-making, contextual influences on preference construction, the causes of and solutions to inefficiency and inequality, and the impact of marketing cues and comparison standards.
prosocial behavior, Intrinsic Reward, Extrinsic Values, Moral Behavior, moral decisions, Global Health, Experimental Economics, development economics, Labor, Human Resources, Johns Hopkins Carey Business School, Johns Hopkins Medicine
Mario Macis, PhD (Economics, University of Chicago) is an associate professor in the research track with expertise in the areas of prosocial behavior, morally controversial transactions, global health, experimental economics, development economics, and labor economics. He is also Affiliate Faculty at the JHU Berman Institute of Bioethics, Associate Faculty at the Armstrong Institute for Patient Safety and Quality at JHU Medicine, Faculty Research Fellow in the National Bureau of Economic Research (NBER), and Research Fellow at the Institute for the Study of Labor (IZA). Dr. Macis has been a consultant for the World Bank, the International Labor Organization, the National Marrow Donor Program, and the United Nations Development Programme.
Health Economics, Children's Health, development economics, Health Policy, Johns Hopkins Carey Business School, congestion pricing
Emilia Simeonova, PhD (Economics from Columbia University in 2008) joined Johns Hopkins Carey Business School in 2013 from Tufts University. Between 2011-2012 she was a research fellow at the Center for Health and Wellbeing at Princeton University. Emilia’s research interests in the economics of health care delivery, patient adherence to therapy and the interaction between physicians and patients, racial disparities in health outcomes, the long-term effects of shocks to children's health and intergenerational transmission of health. Her research has been funded by the National Institutes of Health, the National Science Foundation, the Swedish Research Council and the Danish Academy of Sciences.
Chemistry, Nanoscience, Biophysical Chemistry, materials science
In the quest for molecular-level information, molecular-scale tools are a powerful and desirable scientific goal. Our research program is centered on development of a new class of nanofabricated devices based on nanopores. In its simplest form, a nanopore is nothing more than a molecular-sized hole in an insulating membrane. Yet even in this configuration, it is cable of being used to detect and manipulate single molecules. With careful device engineering, it is possible to create powerful sensors for the detection of disease biomarkers at low levels early in the onset of disease or of trace amounts of toxins -- to name two targets. Configured differently, nanopore-based devices can be used to probe intermolecular interactions that underpin biological function -- ranging from testing new pharmaceutical drug candidates to exploring the fundamental biophysics governing processes such as antibody-antigen recognition. Our research is focused on conceiving, fabricating and optimizing the nanopore devices that will make possible these challenging goals. Research Interests include: How do molecules work, and how can we better put them to work for us? Bioanalytical, biophysical, & materials chemistry and nanoscience.
Oncology, Breast Cancer, Hematologic Cancers
Dr. Priyanka Sharma is an oncologist in Fairway, Kansas and is affiliated with University of Kansas Hospital. She received her medical degree from Baroda Medical College and has been in practice between 11-20 years. Her specialties are: oncologists diagnose and treat cancers of all types. They use diagnostic tools like biopsies, endoscopies, X-ray and other imaging, nuclear medicine, and blood tests. Cancer surgeons, or surgical oncologists, remove tumors, while medical oncologists treat cancers with chemotherapy. Radiation oncologists use multiple forms of radiation in an effort to eliminate tumors.
Roy A. Jensen, MD
Director at The University of Kansas Cancer Center and Director at Kansas Masonic Research Institute (KMCRI)
University of Kansas Cancer CenterPathology, Laboratory Medicine, Anatomy, Cell Biology
Roy A. Jensen, M.D. earned his bachelor’s degree in Biology and Chemistry from Pittsburg State University in 1980. He graduated from Vanderbilt University School of Medicine in 1984, and remained there to complete a residency in Anatomic Pathology and a Surgical Pathology fellowship under the direction of Dr. David L. Page. Following his clinical training he accepted a biotechnology training fellowship at the National Cancer Institute in the laboratory of Dr. Stuart Aaronson. He returned to Vanderbilt in 1991 and was appointed an assistant professor in the Departments of Pathology and Cell Biology. In 1993 Dr. Jensen was appointed as an investigator in the Vanderbilt-Ingram Cancer Center and assumed the management of the Human Tissue Acquisition and Pathology Shared Resource. Dr. Jensen was promoted to associate professor of Pathology and Cell Biology in 1996, and was appointed as an associate professor of Cancer Biology in 2001. In 2004, Dr. Jensen returned home to Kansas and was appointed the William R. Jewell, M.D. Distinguished Kansas Masonic Professor, the director of The University of Kansas Cancer Center, the director of the Kansas Masonic Cancer Research Institute, professor of Pathology and Laboratory Medicine, and professor of Anatomy and Cell Biology at the University of Kansas Medical Center. He also holds appointments as a professor in the Department of Molecular Biosciences at the University of Kansas-Lawrence and as professor in Cancer Biology at The University of Kansas Medical Center. Dr. Jensen is currently serving as president of the Association of American Cancer Institutes (AACI) and is a member of several scientific and professional societies including the American Association for Cancer Research, the American Association for the Advancement of Science, the American Society for Cell Biology, the American Society for Investigative Pathology, and the United States and Canadian Academy of Pathology. He currently has over 150 scientific publications and has lectured widely on the clinical and molecular aspects of breast cancer pathology. Dr. Jensen's research interests are focused on understanding the function of BRCA1 and BRCA2 and their role in breast and ovarian neoplasia; and in the characterization of premalignant breast disease both at the morphologic and molecular levels. His laboratory was instrumental in demonstrating the role of BRCA1 in the growth control of normal and malignant cells and in how loss of functional BRCA1 contributes to the development of breast cancer. Since becoming director of The University of Kansas Cancer Center in 2004, he has recruited a world-class leadership team and successfully led that team in achieving designation for The University of Kansas Cancer Center as a National Cancer Institute designated cancer center.
Gastrointestinal Cancer, Pancreatic Cancer, Colorectal Cancer, Gastric Cancer, Liver Cancer
Weijing Sun, MD, FACP, is a Director of Division of Medical Oncology in University of Kansas School of Medicine, and an Associate Director of University of Kansas Cancer Center. He specializes in the treatment of colorectal cancer. Dr. Sun is board-certified in internal medicine and medical oncology. He received his medical degree from Shanghai Medical College, Fudan University, in Shanghai. He completed his residency in internal medicine at Loyola University Medical Center in Maywood, Ill., and his hematology-oncology fellowship at the University of Pennsylvania in Philadelphia. Dr. Sun is a member of the American Medical Association, the American Society of Clinical Oncology, the American Association of Cancer Research, the Eastern Cooperative Group of Oncology Gastrointestinal Cancer Core Committee, the American College of Physicians – Internal Medicine, the NCI Gastrointestinal Cancer Steering Committee Hepatobiliary Task Force, and serves on the American Society of Clinical Oncology Scientific Program and Membership Committee. In addition, Dr. Sun has been recognized on U.S. News & World Report’s American Top Doctors list.
Raphael Gottardo, PhD
Scientific Director, Translational Data Science Integrated Research Center
Fred Hutchinson Cancer Centerdata-driven immunotherapy, technology convergence, Data science research, translational data, Computational Biology, Computational Science, Bioinformatics, Biostatistics, Stochastic, Flow Cytometry, data-driven research, high-speed genome sequencing
Dr. Raphael Gottardo is a computational biologist who specializes in applying rapidly evolving ideas in data science to solving problems in cancer and related diseases. As scientific director of the Translational Data Science Integrated Research Center, he is at the center of the busy intersection of biology, data science and technology at Fred Hutchinson Cancer Research Center. His goal is to expand data-driven innovations for patients by cultivating a cross-disciplinary environment in which doctors and laboratory scientists work seamlessly with their colleagues in biostatistics and computational sciences to take advantage of the flood of information made possible by advanced technologies. The aim is to bring scientific discoveries from research labs to the bedside sooner using data-driven approaches. To do so, bench scientists and clinical researchers from many corners of the Hutch work collaboratively with experts in data science. Much of his work is focused on profiling the cellular components of the human immune system – using data science to understand how to make immunotherapies work better for patients. “It’s when you get into the details that it really becomes interesting,” he said. “The immune system is very complex, and it turns out we don’t know a whole lot about it yet. Looking at these single-cell technologies generating massive amounts of data has brought me to really cool statistical and computational challenges.” Dr. Gottardo’s own research involves the development of computational tools for vaccine and immunology studies, including high-throughput experiments that may use flow cytometry or high-speed genome sequencing. His current studies include: • Statistical and computational analysis of flow cytometry data • Development of statistical and computational methods for single-cell genomics • Immune responses to malaria and HIV infection and immunization within the Human Immunology Project Consortium (HIPC) • Development of the HIPC database and research portal (www.immunespace.org) • Contribution to the Bioconductor project, an open computing resource for genomics • Leadership for the Vaccine and Immunology Statistical Center of the Collaboration for AIDS Vaccine Discovery of the Bill and Melinda Gates Foundation • Leadership for the Vaccine Statistical Support (VSS) Global Health Vaccine Accelerating Platform (GH-VAP) of the Bill and Melinda Gates Foundation Dr. Gottardo is the J. Orin Edson Foundation Endowed Chair at Fred Hutch and a member of the Vaccine and Infectious Disease and Public Health Sciences Divisions. He, along with other Fred Hutch researchers, is co-leading a collaboration with the Allen Institute for Immunology to chart the human immune system by harnessing big data and emerging technologies. An affiliate professor of statistics at the University of Washington, he teaches courses in stochastic modeling, bioinformatics and statistical computing and supervises biostatistics and statistics doctoral students on statistical-methods research for high-dimensional omics data analysis
---
Dr. David Baskin is board certified by the American Board of Neurological Surgery. He completed his medical training at Mount Sinai School of Medicine of the CUNY, and a residency at the University of California. He completed a fellowship in neural protection at the University of Capetown Medical School. He also completed a fellowship in brain endorphins at the University of California. Baskin is the primary investigator for a number of clinical trials looking at different novel diagnostics and treatments for primary brain tumors and autistic spectrum disorder. His clinical focus is on the treatment of brain and spinal tumors.
---
Dr. Aldona Spiegel certified in plastic surgery by the American Board of Plastic Surgery. She completed her medical training at the University of Ottawa Faculty of Medicine. Spiegel completed a residency in general surgery and plastic surgery at John Hopkins Hospital. She also completed a residency in plastic surgery and a fellowship in microsurgery at Baylor College of Medicine. Spiegel's clinical focus is microsurgery, breast reconstruction, breast sensation and specialized perforator flaps (DIEP, SIEA, SGAP flaps). Her clinical expertise allows her to focus on research in innovative surgical techniques, such as muscle-preserving flaps.
---
Dr. Kevin Varner is board certified by the American Board of Orthopedic Surgery. He completed medical training, an orthopedic surgery residency and a general surgery internship at Baylor College of Medicine. He also completed a clinical fellowship in foot and ankle surgery at John Hopkins University. Varner's clinical areas of interest are tibia fractures and sports-related injuries of the foot and ankle. Varner serves as a consulting physician for the Houston Astros, a head team physician for the Houston Ballet and a team orthopedist for the Houston Texans.
---
Dr. Josh Harris is board certified by the American Board of Orthopedic Surgery in orthopedic sports medicine. He completed his medical training and a residency in orthopedic surgery at Ohio State University College of Medicine. He also completed a fellowship in Orthopedic Surgery Sports Medicine at Rush University Medical Center. His main clinical focus is on sports injury and arthroscopic surgery for the treatment of various sports-related injuries. Harris conducts research in orthopedic sports medicine and hip preservation. Harris serves as the team physician of the Houston Ballet, and the consulting physician of Rice University Athletics.
---
Dr. Vijay Jotwani is board certified by the American Board of Family Medicine in family and sports medicine. He completed his medical training at the University of Illinois College of Medicine. He completed a residency in family medicine at the University of Chicago. Jotwani completed a fellowship in primary care sports medicine at Indiana University. His main clinical focus on the prevention and treatment of sports-related injuries. Jotwani is a consulting physician for the Houston Astros and the Houston Ballet. He is also a primary care physician for the Houston Livestock Show and Rodeo and Rice University Athletics.
sports medicine orthopedics, Professional Athlete Care Team, Tommy John Surgery, Orthopedic Surgeon, sports medicine; pitcher injuries
Neuroendocrine Tumors, Thyroid Cancer, parathyroid tumors, Pancreatic Cancer, Liver Cancer, Minimally Invasive Surgery
Steven K. Libutti, MD, FACS, was appointed as Director of Rutgers Cancer Institute of New Jersey and Vice Chancellor for Cancer Programs, Rutgers Biomedical and Health Sciences in January 2017. In addition to his leadership roles within Rutgers University, Dr. Libutti also serves as Senior Vice President of Oncology Services for RWJBarnabas Health, further strengthening the university’s partnership with the healthcare system. He is also a Professor of Surgery at Rutgers Robert Wood Johnson Medical School and an Affiliated Distinguished Professor in Genetics at the Rutgers School of Arts and Sciences Department of Genetics. Most recently, Dr. Libutti served as Director for the Montefiore Einstein Center for Cancer Care in New York City and was a Professor and Vice Chairman of the Department of Surgery and Professor in the Department of Genetics at Albert Einstein College of Medicine and Montefiore Health System. A surgical oncologist, Dr. Libutti is an internationally known expert in endocrine surgery and the management of neuroendocrine tumors. He is the immediate Past President of the American Association of Endocrine Surgeons. His clinical practice focuses on gastrointestinal malignancies including cancers of the liver and pancreas. The recipient of funding from the National Cancer Institute (NCI) for the past 20 years, Dr. Libutti is also a researcher whose work focuses on developing novel cancer therapies through an understanding of the tumor microenvironment and blood vessel formation in tumors. He is studying tumor neovascular formation and the interaction between tumor cells, endothelial cells and the components of the tumor microenvironment including fibroblasts and cancer stem cells. His work also focuses on a better understanding of the tumor suppressor genes MEN1 and FILIP1L. After graduating magna cum laude from Harvard College, Dr. Libutti received his medical degree from the College of Physicians and Surgeons of Columbia University. He remained at Presbyterian Hospital in New York where he completed his residency in surgery, followed by a fellowship at the NCI in surgical oncology and endocrine surgery. He continued at the NCI where he became a tenured Senior Investigator and Chief of the Tumor Angiogenesis Section in the Surgery Branch. He has published over 280 peer reviewed journal articles, is Editor-in-Chief of the Nature Journal Cancer Gene Therapy, and holds seven U.S. patents. Clinical Expertise: Neuroendocrine tumors, thyroid cancer, parathyroid tumors, pancreatic cancer, liver cancer, gastrointestinal (GI) cancers, minimally invasive surgery, and clinical trials.
Alessandro Grattoni, PhD
Chair, Houston Methodist Research Institute Department of Nanomedicine
Houston Methodist---
Alessandro Grattoni obtained his bachelor's and master's degrees in Mechanical Engineering at the Politecnico of Torino. Grattoni also completed a Postdoctoral Fellowship in nanomedicine and biomedical engineering at The University of Texas Health Science Center. His research focuses on the development and clinical translation of implantable nanofluidic technologies for drug delivery, molecular sieving and cell transplantation. Grattoni areas of expertise are nanomedicine, nanofluidics, drug delivery, implantable devices, silicon technologies, and space medicine.
Mycobacterium Tuberculosis, Group A streptococcus
Biography
Following postdoctoral research at the Institute of Molecular Evolutionary Genetics, Pennsylvania State University, and residency training in laboratory medicine at the Hospital of the University of Pennsylvania, Dr. Musser joined the pathology department, Baylor College of Medicine in Houston, Texas. He advanced through the academic ranks from 1991 to 1998, when he was promoted to professor. Dr. Musser served as the chief of the Laboratory of Human Bacterial Pathogenesis at the National Institute of Allergy and Infectious Diseases from 1999-2003. He joined Houston Methodist Research Institute in 2005 and served as co-director and executive vice president until 2010. In addition to holding the Fondren Presidential Distinguished Chair, Dr. Musser is also the chair of the Department of Pathology and Genomic Medicine and the director of the Center for Molecular and Translational Human Infectious Diseases Research. His research focuses on the molecular basis of host-pathogen interactions in group A Streptococcus and Mycobacterium tuberculosis. He serves on several editorial boards, has received many national and international honors and awards, and has published more than 300 research articles and book chapters.
Description of Research
The goal of Dr. Musser's research is to advance our understanding of pathogen-host interactions, broadly defined. His laboratory uses a highly integrated interdisciplinary research strategy that employs state-of-the-art techniques such as genome sequencing, expression microarray analysis, molecular population genetic analysis, relevant in vivo model systems, and analysis of host factors to gain new information about the molecular basis of infections caused by the human pathogenic bacterium group A Streptococcus (GAS) and Mycobacterium tuberculosis. All of the laboratory's work involves extensive collaboration with local, national, and international investigators with diverse areas of expertise.
One project is to identify key vaccine candidates against group A Streptococcus. This work is performed in collaboration with investigators in the private sector. GAS causes >700 million cases of human disease each year globally, yet no licensed vaccine is available, despite decades of study. Dr. Musser's goal is to use a multi-modality experimental strategy involving molecular dissection of the pathogen and host immunologic response, in vivo disease models, and analysis of clinical material to identify one or more protein antigens that protect humans against GAS pharyngitis and invasive disease.
A second project is designed to elucidate the molecular genetic events contributing to epidemics of GAS infection. This work is done in collaboration with several groups of investigators. The team uses a comprehensive, population-based sample of serotype M3 strains recovered over 16 years from patients with invasive infections as a model system. The project involves extensive (“deep”) comparative genome resequencing and genetic polymorphisms analysis using GAS strains from patients with well-defined clinical phenotype. The goal of this line of research is to understand precise temporal and geographic patterns of strain spread. In addition, the team seeks to define genetic polymorphisms and virulence regulatory circuits in the pathogen that influence clinical phenotype. Recent work has identified a novel virulence circuit involved in the pathogenesis of necrotizing fasciitis, also known as the “flesh-eating” disease. The research also has vaccine and public health implications.
Finally, Dr. Musser has a longstanding interest in the genetic epidemiology of human susceptibility to tuberculosis disease. Using a cohort of extensively defined human tuberculosis patients and controls, his team seeks to define human genetic factors that help to determine why some individuals get tuberculosis disease whereas others who have been exposed to the organism do not. A combination of single nucleotide polymorphism analysis and deep candidate gene resequencing is used, as well as other contemporary human genetic analysis methods.
Areas Of Expertise
Mycobacterium tuberculosis Group A StreptococcusEducation & Training
Residency, University of Pennsylvania Health SystemMD, University of Rochester
Please enter your username and
password to login
-
News keyboard_arrow_right
Latest News Coronavirus News Currently Embargoed News Research News Releases Google Fact Check Research Alert Preprints Marketplace News with Video/Audio Multimedia
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right